恒瑞医药(01276.HK)：SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been accepted for review and included in the priority review process [1] Group 2 - The drug SHR-1918 is classified as a Class 1 innovative drug, indicating its potential significance in the pharmaceutical market [1] - The inclusion in the priority review process suggests that the regulatory body recognizes the drug's importance and aims to expedite its approval [1]